This study presents a case series of 8 patients with progressive keratoconus who, following CXL, received either topical insulin (1 IU/mL, dosage and mixture consistent with prior studies [7]) or artificial tears as an adjunct therapy to standard treatment. This evidence concerns the gene INS and keratoconus.